Targeting drugs to APJ receptor: The prospect of treatment of hypertension and other cardiovascular diseases

Current Drug Targets

Volumn 16, Issue 2, 2015, Pages 148-155

  Cao, Jiangang ^a   Li, Hening ^a   Chen, Linxi ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Agonists; Antagonists; Anti hypertension; Apelin; APJ; Novel compounds; Target

Indexed keywords

APELIN RECEPTOR; CARBOXYLIC ACID; FIBROBLAST GROWTH FACTOR 2; ML 221; UNCLASSIFIED DRUG; APLNR PROTEIN, HUMAN; CARDIOVASCULAR AGENT; G PROTEIN COUPLED RECEPTOR; MOLECULAR LIBRARY;

APOPTOSIS; ARTICLE; ATRIAL FIBRILLATION; AUTOPHAGY; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR SYSTEM EXAMINATION; CAROTID ATHEROSCLEROSIS; CHEMICAL STRUCTURE; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; MUTATION; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; THERAPEUTIC USE;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DESIGN; HUMANS; HYPERTENSION; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; MUTATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923866481     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141128120053     Document Type: Article

References (67)

1. O'Dowd BF, Heiber M, Chan A, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136: 355-60.
2. Bodineau L, Taveau C, Le Quan Sang HH, et al. Data supporting a new physiological role for brain apelin in the regulation of hypothalamic oxytocin neurons in lactating rats. Endocrinology 2011; 152: 3492-503.
3. Gu Q, Zhai L, Feng X, et al. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int 2013; 63: 535-40.
4. Huang ZG, Bai S, Chen L, et al. Effect of puerarin combined with felodipine on mRNA and protein expression of apelin and APJ in renovascular hypertensive rat.. Zhongguo Zhong Yao Za Zhi 2013; 38: 381-5.
5. Najafipour H, Soltani Hekmat A, Nekooian AA, et al. Apelin receptor expression in ischemic and non- ischemic kidneys and cardiovascular responses to apelin in chronic two-kidney-one-clip hypertension in rats. Regul Pept 2012; 178: 43-50.
6. Soltani Hekmat A, Najafipour H, Nekooian AA, et al. Cardiovascular responses to apelin in two-kidney-one-clip hypertensive rats and its receptor expression in ischemic and non-ischemic kidneys. Regul Pept 2011; 172: 62-8.
7. Wattanachanya L, Lu WD, Kundu RK, et al. Increased bone mass in mice lacking the adipokine apelin. Endocrinology 2013; 154: 2069-80.
8. Krist J, Wieder K, Kloting N, et al. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts 2013; 6: 57-69.
9. Geurts L, Lazarevic V, Derrien M, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptinresistant mice: impact on apelin regulation in adipose tissue. Front Microbiol 2011; 2: 149.
10. Dray C, Debard C, Jager J, et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab 2010; 298: E1161-9.
11. Wang Q, Wang GQ, Pang LX, et al. Changes of apelin and its receptor in lung tissue of rats with pulmonary hypertension induced by monocrotaline. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2013; 29: 101-5.
12. Yang L, Su T, Lv D, et al. ERK1/2 mediates lung adenocarcinoma cell proliferation and autophagy induced by apelin-13. Acta Biochim Biophys Sin (Shanghai) 2014; 46: 100-11.
13. Wang Z, Greeley GH, Jr., Qiu S. Immunohistochemical localization of apelin in human normal breast and breast carcinoma. J Mol Histol 2008; 39: 121-4.
14. Lv SY, Yang YJ, Chen Q. Regulation of feeding behavior, gastrointestinal function and fluid homeostasis by apelin. Peptides 2013; 44: 87-92.
15. Antushevich H, Pawlina B, Kapica M, et al. Influence of fundectomy and intraperitoneal or intragastric administration of apelin on apoptosis, mitosis, and DNA repair enzyme OGG1,2 expression in adult rats gastrointestinal tract and pancreas. J Physiol Pharmacol 2013; 64: 423-8.
16. Kang Y, Kim J, Anderson JP, et al. Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res 2013; 113: 22-31.
17. Han S, Wang G, Qi X, et al. Involvement of a Stat3 binding site in inflammation-induced enteric apelin expression. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1068-1078.
18. Lv SY, Yang YJ, Qin YJ, et al. Effect of centrally administered apelin-13 on gastric emptying and gastrointestinal transit in mice. Peptides 2011; 32: 978-82.
19. Taheri S, Murphy K, Cohen M, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002; 291: 1208-12.
20. Guo L, Li Q, Wang W, et al. Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B. Endocr Res 2009; 34: 142-54.
21. Attane C, Daviaud D, Dray C, et al. Apelin stimulates glucose uptake but not lipolysis in human adipose tissue ex vivo. J Mol Endocrinol 2011; 46: 21-8.
22. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008; 118: 3343-54.
23. Kostopoulos CG, Spiroglou SG, Varakis JN, et al. Adiponectin/Tcadherin and apelin/APJ expression in human arteries and periadventitial fat: implication of local adipokine signaling in atherosclerosis? Cardiovasc Pathol 2014; 23: 131-8.
24. LI Lan-fang F, Pan Wei-nan, Chen Feng, LIAO Duan-fang, ZHU Bin-yang, CHEN Lin-xi. Effect of intravenous injection of Apelin on the blood pressure, heart rate and baroreflex sensitivity. China Journal of Modern Medicine 2007; 17: 1442-45.
25. Barnes G, Japp AG, Newby DE. Translational promise of the apelin-- APJ system. Heart (British Cardiac Society) 2010; 96: 1011-6.
26. Langelaan DN, Reddy T, Banks AW, et al. Structural features of the apelin receptor N-terminal tail and first transmembrane segment implicated in ligand binding and receptor trafficking. Biochim Biophys Acta 2013; 1828: 1471-83.
27. Wu H, Cheng XW, Hao C, et al. Regulation of apelin and its receptor expression in adipose tissues of obesity rats with hypertension and cultured 3T3-L1 adipocytes. Exp Anim 2014; 63: 257-67.
28. Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004; 279: 26274-9.
29. Jia YX, Lu ZF, Zhang J, et al. Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 2007; 28: 2023-29.
30. Han X, Zhang DL, Yin DX, et al. Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA. Can J Physiol Pharmacol 2013, 91: 708-14.
31. Modgil A, Guo L, O'Rourke ST, et al. Apelin-13 Inhibits Large- Conductance Ca(2+)-Activated K(+) Channels in Cerebral Artery Smooth Muscle Cells via a PI3-Kinase Dependent Mechanism. PloS one 2013, 8: e83051.
32. Wu D, He L, Chen L. Apelin/APJ system: a promising therapy target for hypertension. Mol Biol Rep 2014; 41(10): 6691-703.
33. Scimia MC, Hurtado C, Ray S, et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 2012; 488: 394-8.
34. Xie F, Liu W, Feng F, et al. A static pressure sensitive receptor APJ promote H9c2 cardiomyocyte hypertrophy via PI3Kautophagy pathway. Acta Biochim Biophys Sin (Shanghai) 2014.
35. Gao LR, Xu RY, Zhang NK, et al. Increased apelin following bone marrow mononuclear cell transplantation contributes to the improvement of cardiac function in patients with severe heart failure. Cell Transplant 2009; 18: 1311-8.
36. Ashley EA, Powers J, Chen M, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005; 65: 73-82.
37. Berry MF, Pirolli TJ, Jayasankar V, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110: II187-193.
38. Lv D, Li H, Chen L. Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 2013; 45: 527-533.
39. Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Adipokines: a novel link between adiposity and carotid plaque vulnerability. Eur J Clin Invest 2012; 42: 1278-86.
40. Fukushima H, Kobayashi N, Takeshima H, et al. Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure. J Cardiovasc Pharmacol 2010; 55: 83-8.
41. Kadoglou NP, Lampropoulos S, Kapelouzou A, et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease--KOZANI STUDY. Transl Res 2010; 155: 238-46.
42. Falcao-Pires I, Goncalves N, Henriques-Coelho T, et al. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009; 296: H2007-2014.
43. Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 2013, 19: 74-82.
44. Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J 2006, 27: 222-6.
45. Karlsson U, Antonsson L, Ljungberg B, et al. Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load. Aids 2012; 26: 1739-44.
46. Cui RR, Mao DA, Yi L, et al. Apelin suppresses apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt signaling pathways. Amino acids 2010; 39: 1193-200.
47. Li L, Li L, Xie F, et al. Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta biochimica et biophysica Sinica 2013; 45: 875-81.
48. Li LL, He L, Zhang Z, Xie F, Guo Y, Xiao J, Chen L, Li J. Effects of apelin-13 on rat bone marrow-derived mesenchymal stem cell proliferation through the AKT/GSK3/cyclin D1 pathway. Int J Pept Res Ther 2014.
49. Zhang Y, Maitra R, Harris DL, et al. Identifying structural determinants of potency for analogs of apelin-13: Integration of Cterminal truncation with structure-activity. Bioorg Med Chem 2014; 22: 2992-7.
50. Maguire JJ, Kleinz MJ, Pitkin SL, et al. Pyr1.apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009, 54: 598-604.
51. Fan X, Zhou N, Zhang X, et al. Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemistry 2003; 42: 10163-8.
52. Azizi Y, Faghihi M, Imani A, et al. Post-infarct treatment with Pyr1.-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides 2013; 46: 76-82.
53. Hamada J, Kimura J, Ishida J, et al. Evaluation of novel cyclic analogs of apelin. Int J Mol Med 2008; 22: 547-52.
54. Lee DK, Saldivia VR, Nguyen T, et al. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005; 146: 231-6.
55. Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003; 84: 1162-72.
56. Macaluso NJ, Pitkin SL, Maguire JJ, et al. Discovery of a competitive apelin receptor (APJ) antagonist. ChemMedChem 2011; 6: 1017-23.
57. Iturrioz X, Alvear-Perez R, De Mota N, et al. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J 2010; 24: 1506-17.
58. Khan P, Maloney PR, Hedrick M, et al. Functional Agonists of the Apelin (APJ) Receptor. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.
59. Mendez M. Renin release: role of SNAREs. Am J Physiol Regul Integr Comp Physiol 2014; 307: R484-R486.
60. Hachtel S, Wohlfart P, Weston J, et al. Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators. In.: Google Patents; 2014.
61. Zhou N, Fang J, Acheampong E, et al. Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. Virology 2003; 312: 196-203.
62. Maloney PR, Khan P, Hedrick M, et al. Discovery of 4-oxo-6- ((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. Bioorg Med Chem Lett 2012; 22: 6656-60.
63. Papadopoulos DP, Mourouzis I, Faselis C, et al. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) 2013; 15: 333-6.
64. Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001; 99: 87-92.
65. Jin G, Yang P, Gong Y, et al. Effects of puerarin on expression of apelin and its receptor of 2K1C renal hypertension rats.. Zhongguo Zhong Yao Za Zhi 2009; 34: 3263-7.
66. Hashimoto T, Kihara M, Imai N, et al. Requirement of apelinapelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 2007; 171: 1705-12.
67. Li F, Li L, Qin X, et al. Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. Front Biosci 2008; 13: 3786-92.